Plato Investment Management Ltd Has $2.16 Million Holdings in Boston Scientific Corporation $BSX

Plato Investment Management Ltd raised its position in Boston Scientific Corporation (NYSE:BSX) by 10.8% in the first quarter, HoldingsChannel reports. The fund owned 21,131 shares of the medical equipment provider’s stock after purchasing an additional 2,061 shares during the quarter. Plato Investment Management Ltd’s holdings in Boston Scientific were worth $2,155,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Brighton Jones LLC lifted its holdings in shares of Boston Scientific by 0.8% in the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after purchasing an additional 226 shares in the last quarter. Bank Pictet & Cie Europe AG lifted its holdings in shares of Boston Scientific by 40.8% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider’s stock valued at $6,529,000 after purchasing an additional 21,173 shares in the last quarter. Highview Capital Management LLC DE lifted its holdings in shares of Boston Scientific by 6.2% in the fourth quarter. Highview Capital Management LLC DE now owns 24,507 shares of the medical equipment provider’s stock valued at $2,189,000 after purchasing an additional 1,439 shares in the last quarter. Gotham Asset Management LLC lifted its holdings in shares of Boston Scientific by 43.7% in the fourth quarter. Gotham Asset Management LLC now owns 11,430 shares of the medical equipment provider’s stock valued at $1,021,000 after purchasing an additional 3,475 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Boston Scientific by 6.0% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 321,764 shares of the medical equipment provider’s stock valued at $28,740,000 after purchasing an additional 18,146 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on BSX shares. Leerink Partners started coverage on Boston Scientific in a report on Monday, June 16th. They issued an “outperform” rating and a $118.00 target price on the stock. Citigroup restated a “buy” rating and issued a $125.00 target price (up previously from $119.00) on shares of Boston Scientific in a report on Thursday, May 22nd. Barclays raised their target price on Boston Scientific from $125.00 to $133.00 and gave the company an “overweight” rating in a report on Thursday, July 24th. Needham & Company LLC reiterated a “buy” rating and set a $115.00 price target on shares of Boston Scientific in a report on Wednesday, May 28th. Finally, Robert W. Baird lifted their price target on Boston Scientific from $117.00 to $123.00 and gave the stock an “outperform” rating in a report on Thursday, July 24th. Three research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $117.79.

Boston Scientific Stock Performance

Shares of Boston Scientific stock opened at $105.32 on Thursday. The business’s fifty day simple moving average is $104.88 and its 200 day simple moving average is $102.24. The firm has a market capitalization of $156.06 billion, a P/E ratio of 62.69, a price-to-earnings-growth ratio of 2.60 and a beta of 0.65. Boston Scientific Corporation has a 12 month low of $80.64 and a 12 month high of $109.50. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. The firm had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business’s revenue was up 22.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insider Transactions at Boston Scientific

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the sale, the executive vice president directly owned 23,600 shares in the company, valued at $2,469,268. The trade was a 42.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Yoshiaki Fujimori sold 2,901 shares of the business’s stock in a transaction on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total value of $310,377.99. Following the completion of the sale, the director owned 2,081 shares in the company, valued at approximately $222,646.19. The trade was a 58.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 174,214 shares of company stock valued at $18,397,457. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.